Protein kinase C-delta inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Chen, Zhihong ^a   Forman, Lora W ^a   Williams, Robert M ^b,c   Faller, Douglas V ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Cancer initiating cell; Protein Kinase C isozymes; Synthetic lethal interaction; Xenograft tumor model

Indexed keywords

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PROTEIN KINASE C-DELTA; PROTEIN KINASE INHIBITORS;

EID: 84893803834     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-90     Document Type: Article

References (74)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111. 10.1038/35102167, 11689955.
2. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648. 10.1038/367645a0, 7509044.
3. Tirino V, Desiderio V, Paino F, De RA, Papaccio F, La NM, et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J 2012
4. Clevers H. Stem cells, asymmetric division and cancer. Nat Genet 2005, 37:1027-1028. 10.1038/ng1005-1027, 16195718.
5. Trumpp A, Wiestler OD. Mechanisms of Disease: cancer stem cells-targeting the evil twin. Nat Clin Pract Oncol 2008, 5:337-347.
6. Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol 2012, 198:281-293. 10.1083/jcb.201202014, 3413352, 22869594.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
8. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
9. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760. 10.1038/nature05236, 17051156.
10. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006, 444:761-765. 10.1038/nature05349, 17151667.
11. Tirino V, Desiderio V, D'Aquino R, De FF, Pirozzi G, Graziano A, et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 2008, 3:e3469. 10.1371/journal.pone.0003469, 2565108, 18941626.
12. Tirino V, Desiderio V, Paino F, De RA, Papaccio F, Fazioli F, et al. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J 2011, 25:2022-2030. 10.1096/fj.10-179036, 21385990.
13. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946-10951. 10.1158/0008-5472.CAN-05-2018, 16322242.
14. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005, 65:3025-3029.
15. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009, 8:158-166. 10.4161/cc.8.1.7533, 3041590, 19158483.
16. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009, 27:2875-2883.
17. Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A 2011, 108:6468-6473. 10.1073/pnas.1005529108, 3081039, 21451132.
18. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008, 68:4311-4320. 10.1158/0008-5472.CAN-08-0364, 2553722, 18519691.
19. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27:1006-1020. 10.1002/stem.30, 2746367, 19415765.
20. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di VA, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008, 15:504-514. 10.1038/sj.cdd.4402283, 18049477.
21. Tirino V, Camerlingo R, Franco R, Malanga D, La RA, Viglietto G, et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 2009, 36:446-453. 10.1016/j.ejcts.2009.03.063, 19464919.
22. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007, 104:10158-10163. 10.1073/pnas.0703478104, 1891215, 17548814.
23. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110. 10.1038/nature05372, 17122772.
24. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009, 69:3382-3389. 10.1158/0008-5472.CAN-08-4418, 2789401, 19336570.
25. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115. 10.1038/nature05384, 17122771.
26. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323. 10.1016/j.stem.2007.06.002, 18371365.
27. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037. 10.1158/0008-5472.CAN-06-2030, 17283135.
28. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature 2008, 451:345-349. 10.1038/nature06489, 3660705, 18202660.
29. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010, 466:133-137. 10.1038/nature09161, 2898751, 20596026.
30. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005, 65:9328-9337. 10.1158/0008-5472.CAN-05-1343, 16230395.
31. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007, 104:973-978. 10.1073/pnas.0610117104, 1783424, 17210912.
32. Li Y, Laterra J. Cancer stem cells: distinct entities or dynamically regulated phenotypes?. Cancer Res 2012, 72:576-580. 10.1158/0008-5472.CAN-11-3070, 3271803, 22298594.
33. Dick JE. Stem cell concepts renew cancer research. Blood 2008, 112:4793-4807. 10.1182/blood-2008-08-077941, 19064739.
34. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011, 17:313-319.
35. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012, 12:133-143.
36. Franken NA, Rodermond HM, Stap J, Haveman J, Van BC. Clonogenic assay of cells in vitro. Nat Protoc 2006, 1:2315-2319. 10.1038/nprot.2006.339, 17406473.
37. Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 2011, 8:486-498. 10.1016/j.stem.2011.04.007, 3633588, 21549325.
38. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005, 65:5506-5511. 10.1158/0008-5472.CAN-05-0626, 15994920.
39. Han ME, Jeon TY, Hwang SH, Lee YS, Kim HJ, Shim HE, et al. Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cell Mol Life Sci 2011, 68:3589-3605. 10.1007/s00018-011-0672-z, 21448722.
40. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284. 10.1038/nrc1590, 15803154.
41. Gomez-Casal R, Bhattacharya C, Ganesh N, Bailey L, Basse P, Gibson M, et al. Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol Cancer 2013, 12:94. 3751356, 23947765.
42. Fabian A, Barok M, Vereb G, Szollosi J. Die hard: are cancer stem cells the Bruce Willises of tumor biology?. Cytometry A 2009, 75:67-74.
43. Valent P, Bonnet D, De MR, Lapidot T, Copland M, Melo JV, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012, 12:767-775. 10.1038/nrc3368, 23051844.
44. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672-679. 10.1093/jnci/djn123, 18445819.
45. Xia S, Forman LW, Faller DV. Protein Kinase C{delta} is required for survival of cells expressing activated p21RAS. J Biol Chem 2007, 282:13199-13210. 10.1074/jbc.M610225200, 3527128, 17350960.
46. Xia S, Chen Z, Forman LW, Faller DV. PKCdelta survival signaling in cells containing an activated p21Ras protein requires PDK1. Cell Signal 2009, 21:502-508. 10.1016/j.cellsig.2008.12.002, 2644428, 19146951.
47. Chen Z, Forman LW, Miller KA, English B, Takashima A, Bohacek RA, et al. The proliferation and survival of human neuroendocrine tumors is dependent upon protein kinase C-delta. Endocr Relat Cancer 2011, 18:759-771. 10.1530/ERC-10-0224, 3527126, 21990324.
48. Takashima A, Faller DV. Targeting the RAS oncogene. Expert Opin Ther Targets 2013
49. Basu A, Pal D. Two faces of protein kinase Cdelta: the contrasting roles of PKCdelta in cell survival and cell death. ScientificWorldJournal 2010, 10:2272-2284.
50. Leitges M, Mayr M, Braun U, Mayr U, Li C, Pfister G, et al. Exacerbated vein graft arteriosclerosis in protein kinase Cdelta-null mice. J Clin Invest 2001, 108:1505-1512. 10.1172/JCI200112902, 209416, 11714742.
51. Zhu T, Chen L, Du W, Tsuji T, Chen C. Synthetic Lethality Induced by Loss of PKC delta and Mutated Ras. Genes Cancer 2010, 1:142-151. 10.1177/1947601909360989, 2964089,2964089, 21031151.
52. Symonds JM, Ohm AM, Carter CJ, Heasley LE, Boyle TA, Franklin WA, et al. Protein kinase C delta is a downstream effector of oncogenic K-ras in lung tumors. Cancer Res 2011, 71:2087-2097. 10.1158/0008-5472.CAN-10-1511, 3271733, 21335545.
53. Strickland LB, Dawson PJ, Santner SJ, Miller FR. Progression of premalignant MCF10AT generates heterogeneous malignant variants with characteristic histologic types and immunohistochemical markers. Breast Cancer Res Treat 2000, 64:235-240. 10.1023/A:1026562720218, 11200773.
54. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, et al. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 2001, 65:101-110. 10.1023/A:1006461422273, 11261825.
55. Takashima A, English B, Chen Z, Cao J, Cui R, Williams RM, et al. Protein Kinase C delta is a therapeutic target in malignant melanoma with NRAS mutation. ACS Chem Biol in press.
56. Guda K, Natale L, Markowitz SD. An improved method for staining cell colonies in clonogenic assays. Cytotechnology 2007, 54:85-88. 10.1007/s10616-007-9083-2, 2267497, 19003022.
57. Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G, et al. Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 1994, 199:93-98. 10.1006/bbrc.1994.1199, 8123051.
58. Susarla BT, Robinson MB. Rottlerin, an inhibitor of protein kinase Cdelta (PKCdelta), inhibits astrocytic glutamate transport activity and reduces GLAST immunoreactivity by a mechanism that appears to be PKCdelta-independent. J Neurochem 2003, 86:635-645. 10.1046/j.1471-4159.2003.01886.x, 12859677.
59. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000, 351:95-105. 10.1042/0264-6021:3510095, 1221339, 10998351.
60. Pan H, Gao F, Papageorgis P, Abdolmaleky HM, Faller DV, Thiagalingam S. Aberrant activation of gamma-catenin promotes genomic instability and oncogenic effects during tumor progression. Cancer Biol Ther 2007, 6:1638-1643. 10.4161/cbt.6.10.4904, 18245958.
61. Papageorgis P, Lambert AW, Ozturk S, Gao F, Pan H, Manne U, et al. Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res 2010, 70:968-978. 10.1158/0008-5472.CAN-09-1872, 2946209, 20086175.
62. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011, 331:1559-1564. 10.1126/science.1203543, 21436443.
63. Wang L, Mezencev R, Bowen NJ, Matyunina LV, McDonald JF. Isolation and characterization of stem-like cells from a human ovarian cancer cell line. Mol Cell Biochem 2012, 363:257-268. 10.1007/s11010-011-1178-6, 22160925.
64. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif 2003, 36(Suppl 1):59-72.
65. Busse A, Letsch A, Fusi A, Nonnenmacher A, Stather D, Ochsenreither S, et al. Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells?. Clin Exp Metastasis 2013, 30:781-789. 10.1007/s10585-013-9578-5, 23519726.
66. Allen-Petersen BL, Carter CJ, Ohm AM, Reyland ME. Protein kinase Cdelta is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer. Oncogene 2013, 10:32-1.
67. Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, et al. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res 2013, 73:6346-6358. 10.1158/0008-5472.CAN-13-1385, 23966295.
68. Bhat-Nakshatri P, Goswami CP, Badve S, Sledge GW, Nakshatri H. Identification of FDA-approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity. Sci Rep 2013, 3:2530.
69. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A 2011, 108:1397-1402. 10.1073/pnas.1018898108, 3029760, 21220315.
70. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 2009, 27:2393-2404. 10.1002/stem.188, 2825688, 19658188.
71. Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res 2011, 71:7226-7237. 10.1158/0008-5472.CAN-10-4660, 21900397.
72. Alison MR, Lin WR, Lim SM, Nicholson LJ. Cancer stem cells: in the line of fire. Cancer Treat Rev 2012, 38:589-598. 10.1016/j.ctrv.2012.03.003, 22469558.
73. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141:583-594. 10.1016/j.cell.2010.04.020, 2882693, 20478252.
74. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80. 10.1016/j.cell.2010.02.027, 2851638, 20371346.